The emerging role of checkpoint inhibitors for rare genitourinary cancers

被引：0
|
作者：
Aragon-Ching, Jeanny B. [1 ]
机构：
[1] Inova Schar Canc Inst, GU Med Oncol, Fairfax, VA 22031 USA
来源：
NATURE REVIEWS UROLOGY | 2021年 / 18卷 / 03期
关键词：
CARCINOMA;
D O I：
10.1038/s41585-021-00426-8
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Rare genitourinary cancers have historically been challenging to treat given the scarcity in incidence, inadequacy of data on treatment and lack of general consensus to guide routine therapy. A phase II multicentre trial shows efficacy of nivolumab and ipilimumab in several cohorts of patients with rare genitourinary cancers.
引用
收藏
页码：133 / 134
页数：2
相关论文
共 50 条
  • [31] Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer
    Gaynor, Nicola
    Crown, John
    Collins, Denis M.
    [J]. SEMINARS IN CANCER BIOLOGY, 2022, 79 : 44 - 57
  • [32] Immune-related adverse events and kidney function decline in patients with genitourinary cancers treated with immune checkpoint inhibitors
    Seethapathy, Harish
    Street, Sarah
    Strohbehn, Ian
    Lee, Meghan
    Zhao, Sophia H.
    Rusibamayila, Nifasha
    Chute, Donald F.
    Gao, Xin
    Michaelson, Marc D.
    Rahma, Osama E.
    Choueiri, Toni K.
    McGregor, Brad
    Sonpavde, Guru
    Salabao, Cristina
    Kaymakcalan, Marina D.
    Wei, Xiao
    Gupta, Shruti
    Motwani, Shveta
    Leaf, David E.
    Reynolds, Kerry L.
    Sise, Meghan E.
    [J]. EUROPEAN JOURNAL OF CANCER, 2021, 157 : 50 - 58
  • [33] Utility of circulating tumor DNA in monitoring treatment response to immune checkpoint inhibitors in patients with advanced genitourinary cancers.
    Jang, Albert
    Jaeger, Ellen B.
    Rauterkus, Grant
    Lieberman, Alexandra
    Huang, Minqi
    Lanka, Sree M.
    Sudhaman, Sumedha
    Mahmood, Tamara
    Pajak, Natalia
    Calhoun, Mark
    Tlemcani, Kaoutar
    ElNaggar, Adam
    Liu, Minetta
    Lewis, Brian E.
    Layton, Jodi Lyn
    Sartor, A. Oliver
    Barata, Pedro C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [34] Mechanism and Management of Checkpoint Inhibitor-Related Toxicities in Genitourinary Cancers
    Li, Haoran
    Sahu, Kamal K.
    Maughan, Benjamin L.
    [J]. CANCERS, 2022, 14 (10)
  • [35] A glance at the emerging diagnostic biomarkers in the most prevalent genitourinary cancers
    Alshahrani, Mohammed Merae
    [J]. SAUDI JOURNAL OF BIOLOGICAL SCIENCES, 2022, 29 (04) : 2072 - 2084
  • [36] Role of the Coagulation System in Genitourinary Cancers: Review
    John, Axel
    Gorzelanny, Christian
    Bauer, Alexander T.
    Schneider, Stefan W.
    Bolenz, Christian
    [J]. CLINICAL GENITOURINARY CANCER, 2018, 16 (01) : E29 - E37
  • [37] Checkpoint inhibitors in gastrointestinal cancers:Expectations and reality
    Hampig Raphael Kourie
    Samer Tabchi
    Marwan Ghosn
    [J]. World Journal of Gastroenterology, 2017, (17) : 3017 - 3021
  • [38] Update on immune checkpoint inhibitors in gynecological cancers
    Heong, Valerie
    Ngoi, Natalie
    Tan, David Shao Peng
    [J]. JOURNAL OF GYNECOLOGIC ONCOLOGY, 2017, 28 (02)
  • [39] Immune checkpoint inhibitors for refractory childhood cancers
    Widemann, Brigitte C.
    [J]. LANCET ONCOLOGY, 2020, 21 (01): : 14 - 15
  • [40] An Overview of Immune Checkpoint Inhibitors in Gynecologic Cancers
    Castellano, Tara
    Moore, Kathleen N.
    Holman, Laura L.
    [J]. CLINICAL THERAPEUTICS, 2018, 40 (03) : 372 - 388
12345